Management of patients with vancomycin-resistant enterococci

Infectious Diseases in Clinical Practice

Volumn 9, Issue 1, 2000, Pages 10-16

  Morris Jr , J Glenn ^a   Roghmann, Mary Claire ^a   Schwalbe, Richard ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; AMPICILLIN; DOXYCYCLINE; LINEZOLID; RIFAMPICIN; VANCOMYCIN;

ANTIBIOTIC RESISTANCE; ANTIMICROBIAL THERAPY; BACTERIAL COLONIZATION; BACTERIAL INFECTION; DISEASE TRANSMISSION; ENTEROCOCCUS; ENTEROCOCCUS FAECALIS; ENTEROCOCCUS FAECIUM; ENTEROCOCCUS GALLINARUM; EPIDEMIC; HOSPITAL INFECTION; HUMAN; IMMUNE DEFICIENCY; MINIMUM INHIBITORY CONCENTRATION; SHORT SURVEY;

EID: 0033986364     PISSN: 10569103     EISSN: None     Source Type: Journal    
DOI: 10.1097/00019048-200009010-00005     Document Type: Short Survey

References (50)

1. Centers for Disease Control and Prevention. Nosocomial enterococci resistant to vancomycin-United States, 1989-1993. MMWR Morb Mortal Wkly Rep 1993;42: 597-9.
2. Morris JG Jr, Shay DK, Hebden JN, et al. Enterococci resistant to multiple antimicrobial agents, including vancomycin. Ann Intern Med 1995;123:250-9.
3. Turenne CY, Hoban DJ, Karlowsky JA, et al. Screening of stool samples for identification of vancomycin-resistant enterococcus isolates should include the methyl-α-D-glucopyranoside test to differentiate nonmotile Enterococcus gallinarum from E. faecium. J Clin Microhiol 1998;36:2333-5.
4. Clark NC, Teixeira LM, Facklam RR, et al. Detection and differentiation of vanC-1, vanC-2, and vanC-3 glycopeptide resistance genes in enterococci. J Clin Microbiol 1998;36:2294-7.
5. Murray BE. The life and times of the enterococcus. Clin Microbiol Rev 1990;3:46-65.
6. Moellering RC. Vancomycin-resistant enterococci. Clin Infect Dis 1998;26:1196-9.
7. Wilson WR, Karchmer AW, Dajani A, et al. Antibiotic treatment of adults with infective endocarditis due to streptococci, enterococci, staphylococci, and HACEK microorganisms. JAMA 1995;274:1706-13.
8. Landman D, Quale JM. Management of infections due to resistan: enterococci: a review of therapeutic options. J Antimicrob Chemother 1997;40:161-70.
9. Schaberg DR, Dillon WI, Terpenning MS, et al. Increasing resistance of enterococci to ciprofloxacin. Antimicrob Agents Chemother 1992;36:2533-5.
10. Geraci JE, Martin WJ. Antibiotic therapy of bacterial endocarditis. VI. Subacute enterococcal endocarditis: clinical, pathologic and therapeutic consideration of 33 cases. Circulation 1954;10:173-94.
11. Leclercq R, Derlot E, Duval J, et al. Plasmid-mediated resistance to vancomycin and teicoplanin in Enterococcus faecium. N Engl J Med 1988;319:157-61.
12. Uttley AHC, Collins CH, Naidoo J, et al. Vancomycin-resistant enterococci. Lancet 1988;1:57-8.
13. Montecalvo MA, Shay DK, Patel P, et al. Bloodstream infections with vancomycin-resistant enterococci. Arch Intern Med 1996;156:1458-62.
14. Papanicolaou GA, Meyers BR, Meyers J, et al. Nosocomial infections with vancomycin-resistant Enterococcus faecium in liver transplant recipients: risk factors for acquisition and mortality. Clin Infect Dis 1996;23:760-6.
15. Tornieporth NG, Roberts RB, John J, et al. Risk factors associated with vancomycin-resistant Enterococcus faecium infection or colonization in 145 matched case patients and control patients. Clin Infect Dis 1996;23:767-72.
16. Bonten MJM, Slaughter S, Ambergen AW, et al. The role of "colonization pressure" in the spread of vancomycin resistant enterococci. Arch Intern Med 1998;158:1127-32.
17. Quale J, Landman D, Saurina G, et al. Manipulation of a hospital antimicrobial formulary to control an outbreak of vancomycin-resistant enterococci. Clin Infect Dis 1996; 23:1020-5.
18. Livornese LL, Dias S, Samel C, et al. Hospital-acquired infection with vancomycin-resistant Enterococcus faecium transmitted by electronic thermometers. Ann Intern Med 1992;117:112-6.
19. Handwerger S, Raucher B, Altarac D, et al. Nosocomial outbreak due to Enterococcus faecium highly resistant to vancomycin, penicillin, and gentamicin. Clin Infect Dis 1993;16:750-5.
20. Bodnar LIR, Noskin GA, Suriano T, et al. Use of in-house studies of molecular epidemiology and full species identification of controlling spread of vancomycin-resistant Enterococcus fecalis isolates. J Clin Microbiol 1996;34: 2129-32.
21. Bonten MJM, Hayden MK, Nathan C, et al. Epidemiology of colonization of patients and environment with vancomycin-resistant enterococci. Lancet 1996;348:1615-9.
22. Noskin GA, Stosor V, Cooper I, et al. Recovery of vancomycin-resistant enterococci on fingertips and environmental surfaces. Infect Control Hosp Epidemiol 1995;16: 577-81.
23. Pfundstein J, Roghmann MC, Schwalbe RS, et al. A randomized trial of surgical antimicrobial prophylaxis with and without vancomycin in organ transplant patients. Clin Transplant 1999;13:245-52.
24. Trick WE, Kuehnert MJ, Quirk SB, et al. Regional dissemination of vancomycin-resistant enterococci resulting from interfacility transfer of colonized patients. J Infect Dis 1999;180:391-6.
25. Roghmann MC, Fink J, Polish L, et al. Colonization with vancomycin-resistant enterococci and survival in chronic hemodialysis patients. Am J Kidney Dis 1998;23:254-7.
26. Schwalbe RA, McIntosh AC, Qaiyumi S, et al. Isolation of vancomycin-resistant enterococci from animal feed in USA [letter]. Lancet 1999;353;722.
27. Roghmann MC, Qaiyumi S, Schwalbe R, et al. Natural history of colonization with vancomycin-resistant Enterococcus faecium [letter]. Infect Control Hosp Epidemiol 1997;18:679-80.
28. Hospital Infection Control Practices Advisory Committee. Recommendations for preventing the spread of vancomycin resistance. Infect Control Hosp Epidemiol 1995; 16:105-13.
29. Austin DJ, Bonten MCM, Weinstein RA, et al. Vancomycin-resistant enterococci in intensive-care hospital settings: transmission dynamics, persistence, and the impact of infection control programs. Proc Natl Acad Sci U S A 1999;96:6908-13.
30. Jochimsen EM, Fish L, Manning K, et al. Control of vancomycin-resistant enterococci at a community hospital: efficacy of patient and staff cohorting. Infect Control Hosp Epidemiol 1999;20:106-9.
31. Deleted in proof.
32. Lai KK, Kelley AL, Melvin ZS, et al. Failure to eradicate vancomycin-resistant enterococci in a university hospital and the cost of barrier precautions. Infect Control Hosp Epidemiol 1998;19:647-52.
33. Lipsky BA, Baker CA, McDonald LL, et al. Improving the appropriateness of vancomycin use by sequential interventions. Am J Infect Control 1999;27:84-90.
34. Roghmann MC, Perdue BE, Polish L. Vancomycin use in a hospital with vancomycin restriction. Infect Control Hosp Epidemiol 1999;20:60-3.
35. Maryland Department of Health and Mental Hygiene. Guidelines for the prevention and control of vancomycin-resistant enterococci (VRE) in long term care facilities. Baltimore: Maryland Department of Health and Mental Hygiene; March 1996, revised September 1996.
36. Chia JKS, Nakata MM, Park SS, et al. Use of bacitracin therapy for infection due to vancomycin-resistant Enterococcus faecium. Clin Infect Dis 1995;21:1520.
37. Armstrong-Evans M, Litt M, McArthur MA, et al. Control of transmission of vancomycin-resistant Enterococcus faecium in a long-term-care facility. Infect Control Hosp Epidemiol 1999;20:312-7.
38. Roghmann MC, Qaiyumi S, Johnson JA, et al. Recurrent vancomycin-resistant Enterococcus faecium bacteremia in a leukemia patient who was persistently colonized with vancomycin-resistant enterococci for two years. Clin Infect Dis 1997;24:514-5.
39. Roghmann MC, McCarter RJ Jr, Brewink J, et al. C. difficile infection is a risk factor for vancomycin resistant enterococcal bacteremia in VRE colonized patients with acute leukemia. Clin Infect Dis 1997;25:1056-9.
40. Mulligan D, Kelly J. Pseudomembranous colitis in a leukemia unit: a report of five fatal cases. J Clin Pathol 1979;32:1237-43.
41. Rampling A, Warren R, Bevan P, et al. Clostridium difficile in hematologic malignancy. J Clin Pathol 1985;28:445-51.
42. Lai KKL. Treatment of vancomycin-resistant Enterococcus faecium infections. Arch Intern Med 1996;156:2579-84.
43. Ramos E, Morris JG Jr, Polish L, et al. Clinical and epidemiologic features of vancomycin resistant enterococcus (VRE) bacteremia in a dialysis center [abstract]. 27th Annual Meeting of the American Society of Nephrology; 1994 Oct 26-29; New Orleans, LA.
44. Lautenbach E, Schuster MG, Bilker WB, et al. The role of chloramphenicol in the treatment of bloodstream infection due to vancomycin-resistant enterococcus. Clin Infect Dis 1998;27:1259-65.
45. Whitman MS, Pitsakis PG, Zausner A, et al. Antibiotic treatment of experimental endocarditis due to vancomycin-and ampicillin-resistant Enterococcus faecium. Antimicrob Agents Chemother 1993;37:2069-73.
46. Brandt CM, Rouse MS, Laue NW, et al. Effective treatment of multidrug-resistant enterococcal experimental endocarditis with combinations of cell wall-active agents. J Infect Dis 1996;173:909-13.
47. Stosor V, Noskin GA, Peterson LR. The management and prevention of vancomycin-resistant enterococci. Infect Med 1996;13:487-488,493-498.
48. Linden PK, Pasculle AW, Manez R, et al. Differences in outcomes for patients with bacteremia due to vancomycin-resistant Enterococcus faecium or vancomycin-susceptible E. faecium. Clin Infect Dis 1996;22:663-70.
49. White S, Qaiyumi S, Johnson RJ, et al. Survey for multiply resistant enterococci from livestock and associated feed [abstract]. The 97th General Meeting of the American Society for Microbiology; 1997 May 4-8; Miami Beach, Florida.
50. Noskin GA, Siddiqui F, Stosor V, et al. Successful treatment of persistent vancomycin-resistant Enterococcus faecium bacteremia with linezolid and gentamicin. Clin Infect Dis 1999;28:689-90.